Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
- Conditions
- Low Back PainChronic Pain
- Interventions
- Drug: NKTR-181 BID tablets
- Registration Number
- NCT02367820
- Lead Sponsor
- Nektar Therapeutics
- Brief Summary
The purpose of this 52-week open label study is to determine the long-term safety of a new opioid molecule, NKTR-181, in patients with moderate to severe chronic low back pain or chronic non-cancer pain.
- Detailed Description
This is an open-label safety and tolerability study in which approximately 600 subjects will receive NKTR-181 for up to 52 weeks. Subjects may include newly enrolled subjects and subjects who have recently completed SUMMIT-07 study.
This study will also investigate the pharmacokinetics of NKTR-181 in patients with chronic low back pain or chronic non-cancer pain.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 638
- Male or non-pregnant, non-nursing female aged 18 to 75 years old
- Clinical diagnosis of moderate to severe, chronic low back or non-cancer pain for at least three months
- Not experiencing adequate pain relief or have failed previous treatment with non-opioid analgesics
- Opioid analgesia is necessary
- Currently taking no less than 10 mg but no more than 60 mg of morphine sulfate equivalents (MSE) per day of opioid analgesics for at least 7 days prior to entry
- Females of child bearing potential must be using a highly effective form of birth control. All subjects must agree to use double-barrier contraception during participation in this study and for at least 2 months after the last dose of the study drug.
- Willing and able to provide informed consent
- History of hypersensitivity, intolerance, or allergy to opioids
- Surgical procedures in the last 4 weeks or plans to undergo surgical procedures during the study period
- Untreated moderate to severe sleep apnea
- Chronic migraines as the primary pain condition
- Cancer related pain
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description NKTR-181 NKTR-181 BID tablets NKTR-181 twice daily (BID) tablets
- Primary Outcome Measures
Name Time Method Number of Participants Reporting Adverse Events Screening baseline through end of study, an average of 57 weeks Count of subjects reporting treatment emergent adverse events
- Secondary Outcome Measures
Name Time Method Change From Baseline in Brief Pain Inventory (BPI) Pain Intensity Item to Week 52 Baseline, monthly change from baseline till the end of study A self-reported scale measuring severity of pain on function. The mean of the 4 intensity items (3-6) is calculated and used as a measure of pain severity. If there were missing items when the pain severity score was calculated, the mean of the completed items in one dimension (dimensions include pain severity and pain interference) were imputed to substitute the missing item, provided that more than 50% of the items in one dimension were completed (Halling, 1999). The range of pain intensity and interference for each question is from 0 to 10. The range of possible scores is from 0 to 70. Higher score indicates relatively worse pain severity and greater interference that pain causes in day to day activities.
Change From Baseline in Brief Pain Inventory (BPI) Pain Interference Item to Week 52 Baseline, monthly change from baseline till the end of study A self-reported scale measuring interference of pain on function. The mean of the 7 interference items was calculated and used as a measure of Pain interference. If there were missing items when the pain interference score was calculated, the mean of the completed items in one dimension (dimensions include pain severity and pain interference) were imputed to substitute the missing item, provided that more than 50% of the items in one dimension were completed (Halling, 1999). The range of pain interference is from 0 to 10. Higher score indicates relatively worse pain problem.
Trial Locations
- Locations (56)
Investigator Site - Stamford
πΊπΈStamford, Connecticut, United States
Investigator Site - Tempe
πΊπΈTempe, Arizona, United States
Investigator Site - Plantation
πΊπΈPlantation, Florida, United States
Investigator Site - Fort Lauderdale
πΊπΈFort Lauderdale, Florida, United States
Investigator Site - Greensboro
πΊπΈGreensboro, North Carolina, United States
Investigator Site - Arlington
πΊπΈArlington, Texas, United States
Investigator Site - West Jordan
πΊπΈWest Jordan, Utah, United States
Investigator Site - Kenosha
πΊπΈKenosha, Wisconsin, United States
Investigator Site - Las Vegas 2
πΊπΈLas Vegas, Nevada, United States
Investigator Site - Cincinnati 1
πΊπΈCincinnati, Ohio, United States
Investigator Site - Cincinnati 2
πΊπΈCincinnati, Ohio, United States
Investigator Site - San Antonio
πΊπΈSan Antonio, Texas, United States
Investigator Site - Phoenix
πΊπΈPhoenix, Arizona, United States
Investigator Site - Winston Salem
πΊπΈWinston-Salem, North Carolina, United States
Investigator Site - Killeen
πΊπΈKilleen, Texas, United States
Investigator Site - Tampa
πΊπΈTampa, Florida, United States
Investigator Site - Clearwater
πΊπΈClearwater, Florida, United States
Investigator Site - Fort Myers
πΊπΈFort Myers, Florida, United States
Investigator Site - Columbus
πΊπΈColumbus, Ohio, United States
Investigator Site - Jacksonville
πΊπΈJacksonville, Florida, United States
Investigator Site - Saraland
πΊπΈSaraland, Alabama, United States
Investigator Site - Little Rock
πΊπΈLittle Rock, Arkansas, United States
Investigator Site - West Palm Beach
πΊπΈWest Palm Beach, Florida, United States
Investigator Site - Gurnee
πΊπΈGurnee, Illinois, United States
Investigator Site - Wichita
πΊπΈWichita, Kansas, United States
Investigator Site - Atlanta
πΊπΈAtlanta, Georgia, United States
Investigator Site - Marietta
πΊπΈMarietta, Georgia, United States
Investigator Site - Shreveport
πΊπΈShreveport, Louisiana, United States
Investigator Site - West Des Moines
πΊπΈWest Des Moines, Iowa, United States
Investigator Site - Bay City
πΊπΈBay City, Michigan, United States
Investigator Site - Louisville
πΊπΈLouisville, Kentucky, United States
Investigator Site - New Orleans
πΊπΈNew Orleans, Louisiana, United States
Investigator Site - Las Vegas 1
πΊπΈLas Vegas, Nevada, United States
Investigator Site - Omaha
πΊπΈOmaha, Nebraska, United States
Investigator Site - Williamsville
πΊπΈWilliamsville, New York, United States
Investigator Site - Norcross
πΊπΈNorcross, Georgia, United States
Investigator Site - Ormond Beach
πΊπΈOrmond Beach, Florida, United States
Investigator Site - Blue Ridge
πΊπΈBlue Ridge, Georgia, United States
Investigator Site - Pinconning
πΊπΈPinconning, Michigan, United States
Investigator Site - Bossier
πΊπΈBossier City, Louisiana, United States
Investigator Site - Saint Louis 1
πΊπΈSaint Louis, Missouri, United States
Investigator Site - Saint Louis 2
πΊπΈSaint Louis, Missouri, United States
Investigator Site - Fargo
πΊπΈFargo, North Dakota, United States
Investigator Site - Jenkintown
πΊπΈJenkintown, Pennsylvania, United States
Investigator Site - Dakota Dunes
πΊπΈDakota Dunes, South Dakota, United States
Investigator Site - Rapid City
πΊπΈRapid City, South Dakota, United States
Investigator Site - Austin
πΊπΈAustin, Texas, United States
Investigator Site - Salt Lake City
πΊπΈSalt Lake City, Utah, United States
Investigator Site - Midlothian
πΊπΈMidlothian, Virginia, United States
Investigator Site - Biloxi
πΊπΈBiloxi, Mississippi, United States
Investigator Site - Orlando
πΊπΈOrlando, Florida, United States
Investigator Site - Beavercreek
πΊπΈBeavercreek, Ohio, United States
Investigator Site - Rochester
πΊπΈRochester, New York, United States
Investigator Site - Memphis
πΊπΈMemphis, Tennessee, United States
Investigator Site - Duncansville
πΊπΈDuncansville, Pennsylvania, United States
Investigator Site - Norfolk
πΊπΈNorfolk, Virginia, United States